Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebyota in Recurrent Clostridioides Difficile Infection
NCT03931941Phase 3Completed
- Sponsor
- Rebiotix Inc.
- Start
- Jul 2019
- Primary completion
- Jul 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of RBX2660 in Clostridioides difficile infection (CDI), sponsored by Rebiotix Inc. Primary endpoint: Safety and Tolerability of RBX2660 in Subjects With Recurrent CDI at 6 months. Started Jul 2019; status: completed.
02
Drugs
RBX2660
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03931941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03931941.